US03152W1099 - Common Stock
These troubled stocks to sell look even worse following WeWork's bankruptcy and will only hurt holders the longer they hold on.
Selling stockholders of Amicus Therapeutics (FOLD) to offer 2.5 million shares for sale, with the company not receiving any proceeds.
3Q 2023 Total Revenue of $103.5M, a 27% Increase Year-Over-Year and 22% at CER Galafold® Quarterly Revenue Surpasses $100M for the First Time ...
PRINCETON, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming...
PRINCETON, N.J., Oct. 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and...
PRINCETON, N.J., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and four posters...
Amicus Therapeutics secures $430M in financing through a loan arrangement and equity offering with Blackstone. Read more here.
Refinancing of Current $400M Debt at Lower Cost and Improved Amortization Schedule Blackstone to also Purchase $30M of Amicus Common Stock PRINCETON,...
/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), congratulates...
Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) Approved in ERT-Experienced Adults First and Only Two-Component Therapy for Eligible Adults...
Amicus Therapeutics sees its Relative Strength Rating move into the 80-plus level.
Amicus Therapeutics expects imminent approval of its Pompe disease treatment, AT-GAA, as indicated in an updated corporate presentation.
PHILADELPHIA, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming...
PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that one oral presentation and five posters across...
Revenue Increased by 17.8% Y-o-Y to RMB8,492.0 Million Adjusted Net Profit Rose by 0.4% to RMB2,925.6 Million Non-COVID Revenue Achieved 59.7% Y-o-Y Growth,...
Biotechnology company Amicus Therapeutics (FOLD) said on Monday that Simon Harford has been appointed CFO, effective immediately.
Daphne Quimi to Retire At Year End PHILADELPHIA, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global...
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain National Institute for...
Amicus Therapeutics press release (FOLD): Q2 GAAP EPS of -$0.15 misses by $0.04.Revenue of $94.5M (+17.1% Y/Y) beats by $4.63M.Cash, cash equivalents, and marketable securities...
1H 2023 Revenue Growth of 16% at CER to $180.8M Raising FY 2023 Galafold® Revenue Growth Guidance to 14%-18% at CER EU Launch of Pombiliti® + Opfolda®...